Skip to content
Wednesday 2 September 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,756.45
-0.30%
DAX
25,839.33
-0.50%
CAC 40
8,280.63
-0.26%
STOXX 50
6,362.15
-0.11%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Thursday 12 November 2020 12:30 pm  |  Updated:  Thursday 12 November 2020 12:50 pm

Vaccine news puts growth back into The City: Moneyfarm’s investment chief

By: Michiel Willems

Add as a preferred source on Google

This week’s news that pharmaceutical giant Pfizer and German manufacturer BioNTech had reached a breakthrough in the development of their Coronavirus vaccine led to one of the heaviest trading days since the height of the pandemic crisis, with nearly $2 trillion changing hands across global markets. 

Firms across The City are in an upbeat mood as the announcement that the vaccine is more than 90 per cent effective in preventing Covid-19 may signal a ‘light at the end of the tunnel’ for many firms.” Morning Wire caught up with Richard Flax, the chief investment officer of London-based digital wealth manager Moneyfarm.

Finally some good news for the financial services industry. 

Monday saw quite an interesting day in financial markets. No, seriously – it was. Pfizer’s announcement prompted a very sharp rally in European equity markets. European equities rose 5% or more, even the long-suffering UK market caught a bid, while safe havens like gold and government bonds sold off. Online brokerages fell over, prompting howls of indignation from day-traders unable to lock in their retirement trades.

Are we not reading too much into this?

Perhaps. But the noteworthy part was the relative weakness in the Nasdaq [which fell 1.5% on the day]. US tech stocks have powered the recovery this year, but the prospect of a viable vaccine sent investors searching for unloved alternatives.

“In a post-Covid world, digital businesses look expensive.”

Richard Flax, CIO of Moneyfarm

Sounds familiar. 

Our interpretation is that we’re back in a growth vs value discussion, here in The City and elsewhere. Remember that in a Covid-19 world, digital businesses rule. They clean up in terms of advertising revenue and sales. Traditional businesses suffer. They have rent, they pump oil, they borrow short and lend long in a world of zero interest rates. And growth stocks crush value stocks, at least in terms of performance. 

But in a post-Covid world, where growth begins to recover, alternatives begin to emerge. Digital businesses look expensive. Their multiples are high, their prospects perhaps over-hyped, at times. And then everyone starts thinking about things like mean reversion and hoary old sayings like ‘trees don’t grow to the sky’, like they said about Amazon in 2014, 15, 16, 17 and so on. It probably explains why Zoom fell 17% on Tuesday.

So what does this mean for the Square Mile? 

It means that we have some interesting questions to answer. First, is the vaccine for real? Can it be distributed on a broad scale even if you need to keep it at -80C until it’s administered? Second, will it prompt a broad-based economic recovery? And third, will that recovery support the unloved stocks that the rally of 2020 has so far largely left behind?

If the answer to all three is yes, then value could outperform growth. European equities could beat the US, and the Nasdaq might languish, if only briefly. This week’s markets suggest that the answer is indeed yes. We’ve had days like that before, and they’ve faded. But maybe this time will be different.

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus
  • London business

Trending Articles

  • Vodafone and Deliveroo look to patch up Reform ties after Yusuf prison threats

  • Trio of firms poised to quit London Stock Exchange as exodus gathers pace

  • Jaguar reveals the Type 01’s screen-free interior

  • Easyjet’s over-60s recruitment push is economically necessary

  • Jim O’Neill: Capital gains tax hike ‘looms’ as top option for Burnham

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Elite Cloud Customers to Outnumber On-Premises for the First Time in Company History as Law Firms Build for AI

    Business Wire
  • European private credit booms as private equity firms are forced to refinance

    Investing
    Investment platform Webull is offering access to UK shares
  • Top AmLaw Firm Hogan Lovells Cadwalader Unifies Global Financial Operations with Elite’s 3E in Six Months

    Business Wire
  • North Highland Awarded on the World’s Best Management Consulting Firms List for Fifth Consecutive Year

    Business Wire
  • Multiplier Raises $35 Million Series B to Build a New Model for Professional Services

    Business Wire
  • The answer to regional inequality isn’t public money, it’s productivity

    Opinion
    Two men setting up a black banner with 10 NORTH in white text on a grey patterned carpet.
  • The World’s Largest AI Companies Built Deployment Arms This Year. Harbor Built One for Law

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook